Cardlytics, Inc. (NASDAQ:CDLX) Receives $6.92 Consensus Target Price from Analysts

Cardlytics, Inc. (NASDAQ:CDLX) has been given an average recommendation of “Hold” by the seven brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $6.92.

A number of research firms recently commented on CDLX. Lake Street Capital lowered Cardlytics from a “buy” rating to a “hold” rating and lowered their price target for the company from $18.00 to $5.00 in a research report on Thursday, August 8th. Bank of America lowered shares of Cardlytics from a “neutral” rating to an “underperform” rating and dropped their price target for the company from $4.00 to $3.50 in a research report on Thursday, August 15th. Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Evercore ISI began coverage on shares of Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a report on Thursday, November 7th.

Insider Activity

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the transaction, the chief executive officer now directly owns 178,519 shares of the company’s stock, valued at approximately $687,298.15. This represents a 11.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alexis Desieno sold 25,118 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $3.43, for a total value of $86,154.74. Following the completion of the sale, the chief financial officer now owns 116,481 shares in the company, valued at approximately $399,529.83. The trade was a 17.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 68,691 shares of company stock valued at $237,767 in the last three months. Company insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Cardlytics

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Cardlytics by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock valued at $32,046,000 after purchasing an additional 57,805 shares during the period. Geode Capital Management LLC raised its holdings in Cardlytics by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after acquiring an additional 73,484 shares during the period. Marshall Wace LLP lifted its position in shares of Cardlytics by 6.8% during the second quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock worth $6,685,000 after acquiring an additional 52,081 shares in the last quarter. RBF Capital LLC boosted its holdings in shares of Cardlytics by 311.9% in the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock worth $1,562,000 after acquiring an additional 369,620 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Cardlytics by 3.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company’s stock valued at $1,249,000 after purchasing an additional 11,388 shares in the last quarter. 68.10% of the stock is owned by hedge funds and other institutional investors.

Cardlytics Stock Up 3.4 %

Cardlytics stock opened at $3.93 on Friday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The firm’s fifty day moving average price is $3.74 and its two-hundred day moving average price is $6.14. The firm has a market capitalization of $199.73 million, a price-to-earnings ratio of -0.64 and a beta of 1.61. Cardlytics has a 1-year low of $2.89 and a 1-year high of $20.52.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. The business had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The company’s quarterly revenue was down 15.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.26) EPS. On average, equities research analysts predict that Cardlytics will post -1.52 earnings per share for the current fiscal year.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.